Valuation: Alector, Inc.

Capitalization 18Cr 16Cr 14Cr 14Cr 25Cr 1.73TCr 26Cr 171.45Cr 67Cr 836.56Cr 68Cr 67Cr 2.91TCr P/E ratio 2026 *
-1.91x
P/E ratio 2027 * -2.55x
Enterprise value -6.56Cr -5.68Cr -5.21Cr -4.9Cr -9.14Cr -625.2Cr -9.28Cr -62Cr -24Cr -302.35Cr -25Cr -24Cr -1.05TCr EV / Sales 2026 *
-9.57x
EV / Sales 2027 * -6.33x
Free-Float
87.03%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-9.67%
1 week-24.31%
Current month-24.31%
1 month-36.38%
3 months-17.42%
6 months+34.02%
Current year+4.81%
1 week 1.62
Extreme 1.625
2.16
1 month 1.62
Extreme 1.625
2.56
Current year 1.5
Extreme 1.5
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
43.32
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 70 01/05/2013
Director of Finance/CFO 53 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 72 19/03/2024
Chairman 77 13/06/2023
Director/Board Member 72 01/10/2018
Date Insider Type Main position Quantity % Market Cap.
03/06Sell

Controller/Auditor

-3,475 0.0031%
02/06Sell

Chief Financial Officer

-19,360 0.0175%
02/06Sell

Founder

-87,216 0.0790%
Change 5d. change 1-year change 3-years change Capi.($)
-9.67%-24.31%+15.96%-77.26% 18Cr
+5.10%+7.04%+49.96%+104.65% 5.5TCr
-0.20%-4.96%+49.75%+46.10% 4.34TCr
-1.69%-8.20%-20.04%-18.99% 2.23TCr
-10.20%-11.87%+29.53%+383.92% 2.04TCr
+0.99%-1.80%+31.49%-25.34% 1.73TCr
+3.90%-7.07%+10.08%-41.83% 1.5TCr
+0.40%+4.40%+24.38%+170.53% 1.32TCr
+0.82%-14.85%+18.57% - 1.17TCr
-0.47%-15.79%-25.14%+694.09% 1.15TCr
Average -1.10%-7.56%+18.45%+137.32% 2.1TCr
Weighted average by Cap. +0.52%-2.96%+28.64%+122.62%

Financials

2026 *2027 *
Net sales 68.57L 59.38L 54.49L 51.26L 95.48L 65Cr 96.97L 6.48Cr 2.52Cr 32Cr 2.57Cr 2.52Cr 109.89Cr 2.29Cr 1.98Cr 1.82Cr 1.71Cr 3.19Cr 218.05Cr 3.24Cr 22Cr 8.41Cr 105.45Cr 8.59Cr 8.4Cr 366.71Cr
Net income -9.41Cr -8.15Cr -7.48Cr -7.04Cr -13Cr -896.81Cr -13Cr -89Cr -35Cr -433.7Cr -35Cr -35Cr -1.51TCr -9.66Cr -8.37Cr -7.68Cr -7.22Cr -13Cr -920.68Cr -14Cr -91Cr -36Cr -445.25Cr -36Cr -35Cr -1.55TCr
Net Debt -25Cr -21Cr -20Cr -18Cr -34Cr -2.36TCr -35Cr -233.42Cr -91Cr -1.14TCr -93Cr -91Cr -3.96TCr -33Cr -28Cr -26Cr -24Cr -45Cr -3.11TCr -46Cr -308.25Cr -119.97Cr -1.5TCr -122.54Cr -119.88Cr -5.23TCr
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
05/26/05 1.635 $ -9.67% 3,64,367
04/26/04 1.810 $ +1.97% 4,49,441
03/26/03 1.775 $ -8.97% 16,91,685
02/26/02 1.950 $ -5.80% 15,61,015
01/26/01 2.070 $ -4.17% 7,05,789
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.635USD
Average target price
3.100USD
Spread / Average Target
+89.60%

Quarterly revenue - Rate of surprise